Abstracts tagged "morbidity and mortality and myositis"

Abstract Number: 389 • 2018 ACR/ARHP Annual Meeting
Risk Factors Associated with Mortality in Inflammatory Myositis: An Asian Perspective
Tyng Yu Chuah¹, Yu Heng Kwan², Nai Lee Lui³ and Warren Fong^4,5,6, ¹Department o Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ²Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore, ³Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁴Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁵Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁶Duke-NUS Medical School, Singapore, Singapore
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune diseases with systemic involvement and excess mortality. We aim to describe the causes and…
Abstract Number: 2321 • 2016 ACR/ARHP Annual Meeting
Early Damage and Mortality in a Cohort of Patients with Myositis Followed up to 20 Years
Sara Guerreiro Castro¹, Pedro Mota² and David A. Isenberg³, ¹Autoimmune Diseases Unit - Serviço Medicina 7.2, Hospital Curry Cabral, Centro Hospitalar Lisboa Central, Lisbon, Portugal, ²Internal Medicine, Hospital da Luz, Lisbon, Portugal, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare diseases, including dermatomyositis (DM), polymyositis (PM) and juvenile dermatomyositis (JDM). Patients often need long-term treatment…
Abstract Number: 294 • 2015 ACR/ARHP Annual Meeting
A Decline in Pulmonary Function over One Year Predicts Outcome in Myositis-Associated Interstitial Lung Disease
Melissa B. Blom¹, Chester V. Oddis², Diane Koontz³ and Rohit Aggarwal⁴, ¹Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in myositis. Clinical trials in myositis-associated ILD (MA-ILD) are lacking due to the absence…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].